Investigational drug · Phase 2
FNP-223
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Progressive Supranuclear Palsy.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "FNP-223"
First trial start
2024
Jul 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FNP-223", any sponsor or status.
Conditions studied
As listed on its trial records.
- Progressive Supranuclear Palsy
Largest trials
Live from ClinicalTrials.gov: studies naming "FNP-223" as an intervention, largest first.
- A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Pivotal-lookingCompleted
Ferrer Internacional S.A.Industry
NCT06355531 · 241 participants · Start Jul 23, 2024 · Primary completion Oct 5, 2026
Drug: FNP-223; Placebo · For: Progressive Supranuclear Palsy
Sites: Carlsbad, California; San Francisco, California; Denver, Colorado · 44 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy Participants.
Pokorny R, Ryan JM, Abd-Elaziz K, et al. · Mov Disord 2026
Also in development for Progressive Supranuclear Palsy
- TertomotideGV1001Phase 33 trials
GemVax & Kael · Moderate to Severe Alzheimer's Disease, Mild to Moderate Alzheimer's Disease, Progressive Supranuclear Palsy
- AMX0035Phase 32 trials
Amylyx Pharmaceuticals Inc. · Wolfram Syndrome, Progressive Supranuclear Palsy, PSP
- NIO752Phase 21 trial
Novartis · Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.